Can a massive biobank unlock the secrets of bladder cancer?
NCT ID NCT07789119
First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time
Summary
Researchers at M.D. Anderson Cancer Center are building a large collection of biological samples and clinical data from people with urothelial carcinoma, a common type of bladder cancer, and related urinary tract cancers. The study will enroll up to 50,000 adults with known or suspected disease, gathering samples during routine care or procedures. The goal is to analyze these samples to better understand the disease and potentially improve how it is diagnosed and treated. This is an observational study, so participants will not receive an experimental treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- biospecimen collection
- What this could lead to
- If successful, this study could help researchers identify biomarkers that lead to earlier detection, better treatment choices, and improved survival for people with urothelial carcinoma.
- What could go wrong
- This is an observational study, not a treatment trial, so it will not directly test a new therapy. The findings may take years to translate into clinical practice, and the large enrollment goal may be challenging to achieve.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2038
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
UT MD Anderson Cancer Center
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligibility Criteria Participants must meet all of the following criteria for enrollment: 1. Age 18 years or older at the time of consent. 2. Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy. 3. Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations. 4. Able to understand and personally provide informed consent. 5. Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document. Exclusion Criteria 1. Age younger than 18 years. 2. Unable to understand the study information or unable to personally provide informed consent. 3. Declines participation. 4. No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives. 5. Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately. 6. Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Biospecimens are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink tumors that resist standard care?
- A simple blood draw could spot bladder Cancer's return
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- A simple urine test could revolutionize bladder cancer detection
- Could a drug combo spare bladder cancer patients from surgery?
- New drug duo takes on advanced bladder cancer in early trial